Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker IOVA · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Oct 16, 2026 | Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Partic… NCT06566092 · Soft Tissue Sarcoma, Primary Central Nervous System Carcino… LN-145/LN-144 | IOVA Iovance Biotherapeutics, Inc. | Phase 1 | Terminated | 5 | Jun 19, 2026 | Registry ↗ |
| Oct 9, 2026 | A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma NCT07741877 · Sarcoma, Soft Tissue Sarcoma (STS) Lifileucel | IOVA Iovance Biotherapeutics, Inc. | Phase 2 | Recruiting | 80 | Sep 1, 2033 | Registry ↗ |
| Oct 1, 2026 | A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma NCT07288203 · Melanoma (Skin Cancer), Unresectable Melanoma Lifileucel | IOVA Iovance Biotherapeutics, Inc. | Phase 2 | Active, not recruiting | 24 | Dec 2027 | Registry ↗ |
| Sep 25, 2026 | Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervic… NCT03108495 · Cervical Carcinoma LN-145, LN-145 + pembrolizumab | IOVA Iovance Biotherapeutics, Inc. | Phase 2 | Terminated | 210 | Aug 22, 2025 | Registry ↗ |
| Sep 24, 2026 | Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Par… NCT05727904 · Metastatic Melanoma, Unresectable Melanoma Lifileucel plus Pembrolizumab, Pembrolizumab with Optional… | IOVA Iovance Biotherapeutics, Inc. | Phase 3 | Recruiting | 670 | Mar 1, 2028 | Registry ↗ |
| Sep 15, 2026 | A Study of IOV-5001 in Adults With Advanced Solid Tumors NCT07743723 · Advanced Solid Tumors, Non-Small Cell Lung Cancer IOV-5001 | IOVA Iovance Biotherapeutics, Inc. | Phase 1/2 | Not yet recruiting | 106 | Mar 2034 | Registry ↗ |
| Jun 26, 2026 | Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer NCT04614103 · Metastatic Non Small Cell Lung Cancer LN-145, LN-145 | IOVA Iovance Biotherapeutics, Inc. | Phase 2 | Recruiting | 170 | Dec 2030 | Registry ↗ |
| Jun 15, 2026 | A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Wil… NCT06940739 · Unresectable Melanoma, Metastatic Melanoma IOV-3001 | IOVA Iovance Biotherapeutics, Inc. | Phase 1/2 | Recruiting | 42 | Jun 2032 | Registry ↗ |
| Jun 11, 2026 | A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants Wit… NCT05361174 · Unresectable Melanoma, Metastatic Melanoma IOV-4001 | IOVA Iovance Biotherapeutics, Inc. | Phase 1/2 | Recruiting | 53 | Sep 2027 | Registry ↗ |
| May 15, 2026 | Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors NCT03645928 · Metastatic Melanoma, Squamous Cell Carcinoma of the Head an… Lifileucel, LN-145 | IOVA Iovance Biotherapeutics, Inc. | Phase 2 | Terminated | 225 | Feb 20, 2026 | Registry ↗ |
| Apr 20, 2026 | Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release NCT05398640 · Unresectable Melanoma, Metastatic Melanoma OOS AMTAGVI | IOVA Iovance Biotherapeutics, Inc. | — | Available | — | — | Registry ↗ |
| Mar 25, 2026 | Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patien… NCT02360579 · Metastatic Melanoma Lifileucel | IOVA Iovance Biotherapeutics, Inc. | Phase 2 | Completed | 220 | Oct 24, 2024 | Registry ↗ |
| Dec 24, 2025 | Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL NCT04155710 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma IOV-2001, Low dose IL-2 | IOVA Iovance Biotherapeutics, Inc. | Phase 1 | Completed | 7 | Nov 11, 2024 | Registry ↗ |
| Oct 30, 2025 | A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer. NCT06481592 · Endometrial Cancer Lifileucel | IOVA Iovance Biotherapeutics, Inc. | Phase 2 | Recruiting | 60 | May 2028 | Registry ↗ |
| Oct 12, 2023 | Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Ce… NCT03083873 · Squamous Cell Carcinoma of the Head and Neck LN-145, LN-145-S1 | IOVA Iovance Biotherapeutics, Inc. | Phase 2 | Completed | 64 | Aug 8, 2022 | Registry ↗ |
| Apr 16, 2019 | Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small C… NCT03419559 · Non Small Cell Lung Cancer LN-145, Durvalumab | IOVA Iovance Biotherapeutics, Inc. | Phase 2 | Withdrawn | 0 | Dec 2021 | Registry ↗ |
16 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:36 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances